Methylprednisolone attenuates interferon-β induced expression of HLA-DR on monocytes
| Autor: | A.D. Crockard, A. G. Droogan, M. T. Treacy, Stanley Hawkins |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Male
Multiple Sclerosis Immunology Stimulation Pharmacology Methylprednisolone Monocytes Autoimmune Diseases law.invention Interferon-gamma law medicine HLA-DR Humans Immunology and Allergy Interferon beta Intravenous methylprednisolone business.industry Multiple sclerosis HLA-DR Antigens Interferon-beta medicine.disease Recombinant Proteins In vitro Gene Expression Regulation Neurology Recombinant DNA Neurology (clinical) business Immunosuppressive Agents medicine.drug |
| Zdroj: | Journal of Neuroimmunology. 70:29-35 |
| ISSN: | 0165-5728 |
| DOI: | 10.1016/s0165-5728(96)00100-2 |
| Popis: | The effect of methylprednisolone on constitutive and interferon-beta (IFN-beta) induced HLA-DR expression on monocytes from multiple sclerosis (MS) patients was investigated. Constitutive HLA-DR expression was reduced by 50% following a single dose (500 mg) of intravenous methylprednisolone (IVMP). Stimulation with natural IFN-beta, in vitro, resulted in a 20 fold increase in HLA-DR expression. Following IVMP, IFN-beta inducible HLA-DR levels were reduced (non-significantly) by 20-30%. Experiments in which monocytes from normal subjects and MS patients were pre-treated in vitro with methylprednisolone prior to IFN-beta stimulation revealed that induction of HLA-DR was significantly inhibited; in contrast, IFN-beta induced HLA-DR expression was not down-regulated following subsequent in vitro treatment with methylprednisolone. These findings suggest that the immunomodulatory effects of IVMP could be attenuated in MS patients receiving regular IFN-beta therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect